AI-Powered Device Provides Real-Time Screening for Early Detection of Heart Failure Symptoms with Chris Darland Peerbridge Health
Release Date: 06/04/2024
Driving Interoperability and Ubiquitous Access to Healthcare Information with Dr. John Blair MedAllies TRANSCRIPT
Empowered Patient Podcast
Dr. John Blair, CEO of MedAllies, was created to address the lack of communication and coordination between healthcare providers and the importance of interoperability in healthcare. While healthcare has become more complicated over the years, with advancements in technology and automation, the lack of reimbursement for coordination of care has contributed to the problem of lack of interoperability. There are incentives and penalties associated with interoperability, including information blocking and the Trust Exchange Framework and Common Agreement (TEFCA) initiative, which aims to...
info_outline
Driving Interoperability and Ubiquitous Access to Healthcare Information with Dr. John Blair MedAllies
Empowered Patient Podcast
Dr. John Blair, CEO of MedAllies, was created to address the lack of communication and coordination between healthcare providers and the importance of interoperability in healthcare. While healthcare has become more complicated over the years, with advancements in technology and automation, the lack of reimbursement for coordination of care has contributed to the problem of lack of interoperability. There are incentives and penalties associated with interoperability, including information blocking and the Trust Exchange Framework and Common Agreement (TEFCA) initiative, which aims to...
info_outline
Universal Approach to Cell Therapy Using SNAP-CAR with Dave Mehalick Coeptis Therapeutics TRANSCRIPT
Empowered Patient Podcast
Dave Mehalick, Chairman, Co-Founder, President, and CEO of Coeptis Therapeutics, focuses on developing cell therapies for oncology and respiratory diseases. They aim to create a universal cell therapy that can be used for various types of cancer and move it from a later line of treatment to a frontline therapy. The company has developed a unique CAR therapy called SNAP-CAR, which utilizes off-the-shelf cells and a targeting mechanism to attack cancer cells at different points, making it difficult for the cells to mutate and evade treatment. Coeptis is conducting clinical trials using its...
info_outline
Universal Approach to Cell Therapy Using SNAP-CAR with Dave Mehalick Coeptis Therapeutics
Empowered Patient Podcast
Dave Mehalick, Chairman, Co-Founder, President, and CEO of Coeptis Therapeutics, focuses on developing cell therapies for oncology and respiratory diseases. They aim to create a universal cell therapy that can be used for various types of cancer and move it from a later line of treatment to a frontline therapy. The company has developed a unique CAR therapy called SNAP-CAR, which utilizes off-the-shelf cells and a targeting mechanism to attack cancer cells at different points, making it difficult for the cells to mutate and evade treatment. Coeptis is conducting clinical trials using its...
info_outline
Unlocking the Power of CRISPR Technology for Drug Development with Ross Bundy CRISPR QC TRANSCRIPT
Empowered Patient Podcast
Ross Bundy, President and CEO of CRISPR QC, shines a light on the current state of CRISPR gene editing technology and how the field has advanced rapidly since the discovery of CRISPR's potential to edit the human genome. The focus of CRISPR technology has primarily been on curing rare and genetic diseases, but there is also potential for targeting cancer tumors' resistance to chemotherapy and the development of customized therapies for various indications. The services offered by CRISPR QC include a unique sensor platform and data analytics capability to monitor and control the gene editing...
info_outline
Unlocking the Power of CRISPR Technology for Drug Development with Ross Bundy CRISPR QC
Empowered Patient Podcast
Ross Bundy, President and CEO of CRISPR QC, shines a light on the current state of CRISPR gene editing technology and how the field has advanced rapidly since the discovery of CRISPR's potential to edit the human genome. The focus of CRISPR technology has primarily been on curing rare and genetic diseases, but there is also potential for targeting cancer tumors' resistance to chemotherapy and the development of customized therapies for various indications. The services offered by CRISPR QC include a unique sensor platform and data analytics capability to monitor and control the gene editing...
info_outline
Therapeutic Cancer Vaccines with Nicolas Poirier OSE Immunotherapeutics TRANSCRIPT
Empowered Patient Podcast
Nicolas Poirier, CEO of OSE Immunotherapeutics, uses immunology and molecular engineering to develop innovative immunotherapies for oncology, inflammation, autoimmune diseases, and organ transplant. The same immune cells, lymphocytes and macrophages, are involved in both immuno-oncology and immuno-inflammation, and OSE aims to re-educate these cells to recognize and eliminate cancer cells or restore immune tolerance in autoimmune diseases. He also discusses the potential of cancer vaccines in re-educating the immune system to target cancer cells, and the importance of combination...
info_outline
Therapeutic Cancer Vaccines with Nicolas Poirier OSE Immunotherapeutics
Empowered Patient Podcast
Nicolas Poirier, CEO of OSE Immunotherapeutics, uses immunology and molecular engineering to develop innovative immunotherapies for oncology, inflammation, autoimmune diseases, and organ transplant. The same immune cells, lymphocytes and macrophages, are involved in both immuno-oncology and immuno-inflammation, and OSE aims to re-educate these cells to recognize and eliminate cancer cells or restore immune tolerance in autoimmune diseases. He also discusses the potential of cancer vaccines in re-educating the immune system to target cancer cells, and the importance of combination...
info_outline
Innovative Blood Collection Device Boosts Participation in Decentralized Clinical Trials with Ben Casavant Tasso TRANSCRIPT
Empowered Patient Podcast
Ben Casavant, Co-Founder and CEO of Tasso, focuses on making diagnostics more accessible to patients that allow collection of blood samples at home. Their customers include pharmaceutical companies conducting research and healthcare providers. Using Tasso's technology in decentralized clinical trials allows for easier recruitment, increased patient participation, and more data collection. The simplicity and ease of use of Tasso's blood collection device have resulted in positive patient responses and improved retention rates in clinical trials. They offer liquid and dried blood collection...
info_outline
Innovative Blood Collection Device Boosts Participation in Decentralized Clinical Trials with Ben Casavant Tasso
Empowered Patient Podcast
Ben Casavant, Co-Founder and CEO of Tasso, focuses on making diagnostics more accessible to patients that allow collection of blood samples at home. Their customers include pharmaceutical companies conducting research and healthcare providers. Using Tasso's technology in decentralized clinical trials allows for easier recruitment, increased patient participation, and more data collection. The simplicity and ease of use of Tasso's blood collection device have resulted in positive patient responses and improved retention rates in clinical trials. They offer liquid and dried blood collection...
info_outlineChris Darland, President and CEO of Peerbridge Health, discusses technology breakthroughs that enable early, low-cost detection of heart issues with a cardiac monitor that uses AI to analyze heart rhythms over time to detect patterns that may indicate heart failure. The device is based on ECG technology that drives the Holter monitor and delivers a full 12-lead ECG with a volumetric 3D view of the heart. The goal is to reach more patients who may not proactively seek medical attention and provide early intervention and treatment.
Chris explains, " I think the problem with the current state is largely that it's too late. And I say that to mean that 80% of all heart failure cases today are getting caught after an emergency room visit. So, it's not necessarily that we don't have the tools to find heart failure and the cardiologists and expertise to identify it, but we're not getting it in time. So if you are one of those patients who, let's say, are caught earlier or maybe unfortunately when you come through the ER, a lot of the tools are existing in the hospital. So you'll get an ultrasound, an echo, to get a view of your heart. We'll do an ECG in the hospital and potentially a cardiac MRI. There's a suite of tools available in the acute care setting that can get to this conclusion relatively quickly if you have all the tools right in front of you."
"The nice part about it is it's relatively accepted from a workflow perspective, a tool that's used quite commonly and has become exceedingly convenient over the last five to 10 years. There is a lot of innovation in a handful of companies to make it easy to wear, light, waterproof, etc. And when we think through the innovation we're working through right now, it's essentially using that tool and the output of this ambulatory cardiac monitor that we have in Peerbridge. Then doing some interesting AI advanced diagnostics on top of it to pick up patterns that were maybe lost historically or potentially missed based on signal fidelity of devices that were in the market. Then using those patterns to try to get a head start on heart failure diagnosis as well as a handful of other things we can show they do."
#PeerbridgeHealth #Cardiology #Cardiologists #ECG #HeartHealth #HeartFailure #EarlyDetection #RemotePatientMonitoring
